US2003100574A1PendingUtilityA1

Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies

44
Priority: Nov 15, 2001Filed: Nov 14, 2002Published: May 29, 2003
Est. expiryNov 15, 2021(expired)· nominal 20-yr term from priority
Inventors:Nestor Antonio Lagos Wilson
A61P 29/00A61P 25/00A61P 27/02A61P 17/02A61P 13/10A61K 38/4886A61K 31/519A61K 31/40A61K 31/495A61K 31/52A61P 21/02A61P 17/00A61K 31/4168A61P 1/00A61P 21/00
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Pharmaceutical compositions comprising tricyclic 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission are provided.

Claims

exact text as granted — not AI-modified
What is claimed:  
     
         1 . A pharmaceutical composition for interfering with neuronal transmission, the composition comprising an effective amount of at least one compound represented by the following structure:  
       
         
           
           
               
               
           
         
       
       wherein R 1  and R 5  are independently H or OH; R 2  and R 3  are independently H or OSO 3 ; and R 4  is independently COONH 2 , OH, H, COONHSO 3  or COOCH 3 ; and a pharmacologically acceptable carrier.  
     
     
         2 . The composition of  claim 1 , wherein the composition comprises a mixture of Gonyautoxin 2, Gonyautoxin 3 and Saxitoxin.  
     
     
         3 . The composition of  claim 1 , wherein the composition comprises a mixture of Gonyautoxin 4, Gonyautoxin 1, Gonyautoxin 5, Gonyautoxin 3 and Gonyautoxin 2.  
     
     
         4 . The composition of  claim 1 , wherein the composition comprises a mixture of Saxitoxin, neoSaxitoxin, Decarbamoyl-Saxitoxin, Gonyautoxin 3 and Gonyautoxin 2.  
     
     
         5 . The composition of  claim 1 , further comprising Botulin A toxin.  
     
     
         6 . The composition of  claim 1 , wherein the carrier is water.  
     
     
         7 . The composition of  claim 1 , wherein the carrier is 0.09% Sodium Chloride.  
     
     
         8 . The composition of  claim 1 , wherein the composition comprises about twenty to about forty units of the compound per milliliter of total solution.  
     
     
         9 . The composition of  claim 8 , wherein the composition comprises forty units of the compound per milliliter of total solution.  
     
     
         10 . The composition of  claim 1 , wherein the compound is diluted in a solution of acetic acid.  
     
     
         11 . A preparation for facial rejuvenation comprising an effective amount of the composition of  claim 1  and a facial cream.  
     
     
         12 . The preparation of  claim 11 , wherein said composition comprises about twenty to about forty units of the compound per milliliter of total solution.  
     
     
         13 . The preparation of  claim 11 , wherein said composition comprises about forty units of the compound per milliliter of total solution.  
     
     
         14 . The preparation of  claim 11 , wherein said carrier is water.  
     
     
         15 . The preparation of  claim 11 , wherein said compound is diluted in a solution of acetic acid.  
     
     
         16 . The preparation of  claim 11 , wherein the composition comprises a mixture of Gonyautoxin 2, Gonyautoxin 3 and Saxitoxin.  
     
     
         17 . The preparation of  claim 11 , wherein the composition comprises a mixture of Saxitoxin, neoSaxitoxin, Decarbamoyl-Saxitoxin, Gonyautoxin 3 and Gonyautoxin 2.  
     
     
         18 . The preparation of  claim 11  wherein the composition comprises a mixture of Gonyautoxin 4, Gonyautoxin 1, Gonyautoxin 5, Gonyautoxin 3 and Gonyautoxin 2.  
     
     
         19 . The preparation of  claim 11 , further comprising Botulin A toxin.  
     
     
         20 . A method of interfering with neuronal transmission comprising contacting a neuron with an effective amount of the composition of  claim 1 .  
     
     
         21 . The method of  claim 20 , wherein the composition comprises a mixture of Gonyautoxin 2, Gonyautoxin 3 and Saxitoxin.  
     
     
         22 . The method of  claim 20 , wherein the composition comprises a mixture of Saxitoxin, neoSaxitoxin, Decarbamoyl-Saxitoxin, Gonyautoxin 3 and Gonyautoxin 2.  
     
     
         23 . The method of  claim 20 , wherein the composition comprises a mixture of Gonyautoxin 4, Gonyautoxin 1, Gonyautoxin 5, Gonyautoxin 3 and Gonyautoxin 2.  
     
     
         24 . The method of  claim 20 , wherein the composition further comprises Botulin A toxin.  
     
     
         25 . The method of  claim 20 , wherein about 100 to about 800 microliters of said composition is contacted with said neuron.  
     
     
         26 . The method of  claim 20 , wherein less than one milliliter of said composition is contacted with said neuron.  
     
     
         27 . The method of  claim 20 , wherein contacting an effective amount of the composition of  claim 1  with a neuron comprises injecting the composition of  claim 1  in an area proximate to the neuron.  
     
     
         28 . The method of  claim 20 , wherein said composition comprises about forty units of the compound per milliliter of total solution.  
     
     
         29 . The method of  claim 20 , wherein said composition comprises about 20 to about 40 units of the compound per milliliter of total solution.  
     
     
         30 . The method of  claim 20 , wherein said compound is diluted in a solution of acetic acid.  
     
     
         31 . The method of  claim 20 , wherein said neuron is in a muscle.  
     
     
         32 . The method of  claim 31 , wherein said muscle is inside a human face.  
     
     
         33 . A method interfering with muscle contraction comprising contacting a muscle with an effective amount of the composition of  claim 1 .  
     
     
         34 . The method of  claim 33 , wherein the composition of  claim 1  comprises a mixture of Gonyautoxin 2, Gonyautoxin 3 and Saxitoxin.  
     
     
         35 . The method of  claim 33 , wherein the composition of  claim 1  comprises a mixture of Saxitoxin, neoSaxitoxin, Decarbamoyl-Saxitoxin, Gonyautoxin 3 and Gonyautoxin 2.  
     
     
         36 . The method of  claim 33 , wherein the composition of  claim 1  comprises a mixture of Gonyautoxin 4, Gonyautoxin 1, Gonyautoxin 5, Gonyautoxin 3 and Gonyautoxin 2.  
     
     
         37 . The method of  claim 33 , wherein the composition of  claim 1  further comprises Botulin A toxin.  
     
     
         38 . The method of  claim 33 , wherein the composition of  claim 1  comprises about 20 to about 40 units of the compound per milliliter of the carrier.  
     
     
         39 . The method of  claim 33 , wherein the carrier is acetic acid.  
     
     
         40 . The method of  claim 33 , wherein the composition of  claim 1  comprises about twenty to about forty units of the compound per milliliter of total solution.  
     
     
         41 . The method of  claim 33 , wherein the composition of  claim 1  comprises about forty units of the compound per milliliter of total solution.  
     
     
         42 . The method of  claim 33 , wherein contacting an effective amount of the composition of  claim 1  with a muscle comprises injecting the composition into an area proximate to the muscle.  
     
     
         43 . The method of  claim 42 , wherein no more than one milliliter of the composition of  claim 1  is injected into an area proximate to the muscle per injection point.  
     
     
         44 . The method of  claim 42 , wherein about 100 to about 800 microliters of the composition of  claim 1  is injected into an area proximate to the muscle per injection point.  
     
     
         45 . The method of  claim 33 , wherein the muscle is inside a human face.  
     
     
         46 . The method of  claim 33 , wherein the carrier is 0.09% sodium chloride.  
     
     
         47 . The method of  claim 33 , wherein the compound is diluted in a solution of acetic acid.

Join the waitlist — get patent alerts

Track US2003100574A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.